Ken Yamada

This inventor holds 15 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Novartis Ag, University of Massachusetts. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ken Yamada. Retrieved from https://idiyas.com/inventor/ken-yamada-5p54fe7u

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 4)

% Patents Active = 93.3

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 16)

Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 7(Granted Patents)

Location History:

Cambridge, MA (US) (2014)
Brookline, MA (US) (2013 - 2022)
Boston, MA (US) (2012 - 2024)

Company Filing History:

University of Massachusetts

patents

Years Active: 2012-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692498 - MODIFIED OLIGONUCLEOTIDES TARGETING SNPs (2026-07-28),

2. 12534724 - SYNTHETIC OLIGONUCLEOTIDES HAVING REGIONS OF BLOCK AND CLUSTER MODIFICATIONS (2026-01-27),

3. 12146136 - Synthesis of modified oligonucleotides with increased stability (2024-11-19),

4. 12077758 - Oligonucleotides for SARS-CoV-2 modulation (2024-09-03),

5. 12024706 - Modified oligonucleotides targeting SNPs (2024-07-02),

6. 11827882 - Modified oligonucleotides targeting SNPs (2023-11-28),

7. 11820985 - Modified oligonucleotides with increased stability (2023-11-21),

8. 11530213 - Naphthyridinone derivatives and their use in the treatment of arrhythmia (2022-12-20),

9. 10844055 - Naphthyridinone derivatives and their use in the treatment of arrhythmia (2020-11-24),

10. 10266531 - Naphthyridinone derivatives and their use in the treatment of arrhythmia (2019-04-23),

11. 9867811 - Method of treating atherosclerosis in high triglyceride subjects (2018-01-16),

12. 8759365 - Organic compounds (2014-06-24),

13. 8440682 - 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors (2013-05-14),

14. 8420641 - Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives (2013-04-16),

15. 8193349 - 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors (2012-06-05),

Title: Ken Yamada: Innovator in Cardiovascular Therapeutics

Introduction

Ken Yamada, an accomplished inventor based in Brookline, MA, has made significant contributions to the field of pharmaceutical innovations. With a total of eight patents to his name, Yamada's work primarily focuses on the development of compounds aimed at treating cardiovascular conditions, particularly arrhythmias. His dedication to advancing medical science exemplifies the spirit of innovation that drives the pharmaceutical industry.

Latest Patents

Among his latest contributions, Yamada has been instrumental in the invention of naphthyridinone derivatives aimed at treating arrhythmia. His recent patent details the provision of compounds with the formula (I) or pharmaceutically acceptable salts thereof, along with a method for manufacturing these compounds. The invention showcases therapeutic uses that could revolutionize treatment strategies for heart rhythm disorders. Additionally, it includes a combination of pharmacologically active agents and a pharmaceutical composition, reflecting his commitment to improving healthcare outcomes.

Career Highlights

Yamada is currently employed at Novartis AG, a company recognized for its dedication to providing innovative healthcare solutions. His role involves extensive research and development, allowing him to partake in pivotal projects that push the boundaries of medical science. Throughout his career, Yamada has been at the forefront of drug development, with a focus on creating effective treatments that address pressing health challenges in cardiovascular care.

Collaborations

Collaboration has been a cornerstone of Yamada's success in the field. He has worked alongside notable colleagues, including Kayo Yasoshima and Muneto Mogi, fostering a collaborative environment that enhances creativity and accelerates the research process. Together, they contribute to groundbreaking discoveries that hold the potential to save lives.

Conclusion

Ken Yamada's innovative spirit and dedication to advancing medical therapies make him a noteworthy figure in the pharmaceutical industry. With several patents to his credit and a strong collaborative network, Yamada continues to have a lasting impact on the treatment of cardiovascular diseases. His work not only represents individual achievement but also signifies the collective effort towards improving health and well-being on a global scale.

Profile summary based on public USPTO records.